Trial Profile
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 03 Nov 2020 Planned End Date changed from 19 Dec 2019 to 26 Sep 2023.
- 06 Nov 2019 Results released in 61st Annual Meeting and Exposition of the American Society of Hematology.
- 29 Aug 2019 Planned End Date changed from 26 Sep 2020 to 19 Dec 2019.